Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.

Even more impressive is the fact the JS8 PHEV can travel up to 84 km on pure electric power based on the WLTC cycle. With a ...

That’s right. Kia has teased the upcoming crossover called the Syros. For now, the Korean manufacturer intends to offer it in ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Discover how to navigate CMC processes effectively in drug development. Learn from industry leaders and ensure your project’s ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Rocket Lab USA shares jumped 28.7% to $18.86 in the pre-market trading session. Here are some other stocks moving in ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

Kia Motors has officially announced its upcoming compact SUV, the Syros, anticipated to hit the global market in the coming weeks with a full launch likely early next year. This model, previously ...